Published in Ann Intern Med on May 15, 1990
Who benefits from medical interventions? BMJ (1994) 5.58
Open access clinic providing HIV-I antibody results on day of testing: the first twelve months. BMJ (1991) 3.17
Evidence-based guidelines for universal counselling and offering of HIV testing in pregnancy in Canada. CMAJ (1998) 3.05
Complete nucleotide sequence, genome organization, and biological properties of human immunodeficiency virus type 1 in vivo: evidence for limited defectiveness and complementation. J Virol (1992) 2.86
1592U89, a novel carbocyclic nucleoside analog with potent, selective anti-human immunodeficiency virus activity. Antimicrob Agents Chemother (1997) 2.31
Clinical research, prophylaxis, therapy, and care for HIV disease in Africa. Am J Public Health (1993) 2.07
The significance of activation markers on CD8 lymphocytes in human immunodeficiency syndrome: staging and prognostic value. Clin Exp Immunol (1992) 1.98
Use of virologic assays for detection of human immunodeficiency virus in clinical trials: recommendations of the AIDS Clinical Trials Group Virology Committee. J Clin Microbiol (1993) 1.78
Specific, sensitive, and rapid assay for human immunodeficiency virus type 1 pol mutations associated with resistance to zidovudine and didanosine. J Clin Microbiol (1995) 1.57
Early HIV infection: to treat or not to treat? BMJ (1990) 1.51
Managing HIV disease after Delta. BMJ (1996) 1.49
Compliance with public sector HIV medical care. J Natl Med Assoc (1995) 1.49
Anti-human immunodeficiency virus synergism by zidovudine (3'-azidothymidine) and didanosine (dideoxyinosine) contrasts with their additive inhibition of normal human marrow progenitor cells. Antimicrob Agents Chemother (1991) 1.45
Survival differences in European patients with AIDS, 1979-89. The AIDS in Europe Study Group. BMJ (1994) 1.41
Synergistic inhibition of replication of human immunodeficiency virus type 1, including that of a zidovudine-resistant isolate, by zidovudine and 2',3'-dideoxycytidine in vitro. Antimicrob Agents Chemother (1992) 1.25
5-Chloro-2',3'-dideoxy-3'-fluorouridine (935U83), a selective anti-human immunodeficiency virus agent with an improved metabolic and toxicological profile. Antimicrob Agents Chemother (1994) 1.25
Factors associated with lack of awareness of HIV infection before diagnosis of AIDS. BMJ (1993) 1.22
Systematic review and meta-analysis of evidence for increasing numbers of drugs in antiretroviral combination therapy. BMJ (2002) 1.21
Markers predicting progression of human immunodeficiency virus-related disease. Clin Microbiol Rev (1994) 1.19
pol mutations conferring zidovudine and didanosine resistance with different effects in vitro yield multiply resistant human immunodeficiency virus type 1 isolates in vivo. Antimicrob Agents Chemother (1993) 1.14
Cost effectiveness analysis of early zidovudine treatment of HIV infected patients. BMJ (1993) 1.14
Determination of CD4 and CD8 lymphocyte subsets by a new alternative fluorescence immunoassay. Clin Diagn Lab Immunol (1995) 1.09
Surrogate markers for survival in patients with AIDS and AIDS related complex treated with zidovudine. BMJ (1991) 1.08
Decreased human immunodeficiency virus type 1 plasma viremia during antiretroviral therapy reflects downregulation of viral replication in lymphoid tissue. Proc Natl Acad Sci U S A (1995) 0.99
Antiviral properties of aminodiol inhibitors against human immunodeficiency virus and protease. Antimicrob Agents Chemother (1995) 0.98
Long-term exposure to zidovudine delays cell cycle progression, induces apoptosis, and decreases telomerase activity in human hepatocytes. Toxicol Sci (2009) 0.98
When should asymptomatic patients with HIV infection be treated with zidovudine? BMJ (1992) 0.97
Primary care and HIV disease. J Gen Intern Med (1991) 0.97
Antiviral therapy: current concepts and practices. Clin Microbiol Rev (1992) 0.96
Effects of dideoxyinosine and dideoxycytidine on the intracellular phosphorylation of zidovudine in human mononuclear cells. Br J Clin Pharmacol (1994) 0.96
After Concorde. BMJ (1993) 0.93
Antiretroviral therapy: reverse transcriptase inhibition. Antimicrob Agents Chemother (1992) 0.92
Antiretroviral Drug-Associated Oral Lichenoid Reaction in HIV Patient: A Case Report. Int J Dent (2010) 0.87
Induction of humoral and cell-mediated anti-human immunodeficiency virus (HIV) responses in HIV sero-negative volunteers by immunization with recombinant gp160. J Clin Invest (1993) 0.87
The progression of untreated HIV-1 infection prior to AIDS. Am J Public Health (1992) 0.86
Strategies for control of zidovudine concentrations in serum. Antimicrob Agents Chemother (1995) 0.86
Synergistic inhibition of human immunodeficiency virus type 1 replication by 5-ethyl-1-ethoxymethyl-6-(phenylthio)uracil (E-EPU) and azidothymidine in vitro. Antimicrob Agents Chemother (1991) 0.85
Natural history of HIV-1 infection and predictors of survival in a cohort of HIV-1 seropositive injecting drug users. J Natl Med Assoc (1996) 0.84
Surrogate end points in clinical trials. BMJ (1991) 0.83
Effects of incarceration on HIV-infected individuals. J Natl Med Assoc (1996) 0.83
Comparison of culture- and non-culture-based methods for quantification of viral load and resistance to antiretroviral drugs in patients given zidovudine monotherapy. J Clin Microbiol (1998) 0.82
Zidovudine for early human immunodeficiency virus (HIV) infection: who, when, and how? Ann Intern Med (1990) 0.82
Long-term tolerance and efficacy of 3'-azidothymidine and 3'-fluorothymidine treatment of asymptomatic monkeys infected with simian immunodeficiency virus. Antimicrob Agents Chemother (1992) 0.81
Interference of cell cycle progression by zidovudine and lamivudine in NIH 3T3 cells. Mutagenesis (2008) 0.81
Biochemical and haematological changes in HIV subjects receiving winniecure antiretroviral drug in Nigeria. J Biomed Sci (2013) 0.81
Antiretroviral treatment reverses HIV-induced reduction in the expression of surface antigens on alveolar macrophages in AIDS patients. Clin Exp Immunol (1993) 0.80
Impairment of tritan colour vision after initiation of treatment with zidovudine in patients with HIV disease or AIDS. Br J Ophthalmol (1993) 0.80
Recent trends in early stage response to combination antiretroviral therapy in Australia. Antivir Ther (2014) 0.79
Selection of recombinant, library-derived antibody fragments against p24 for human immunodeficiency virus type 1 diagnostics. Clin Diagn Lab Immunol (1998) 0.79
Frequency and determinants of use of antiretroviral and prophylactic therapies against Pneumocystis carinii Pneumonia (PCP) before AIDS diagnosis in Italy. Eur J Epidemiol (1998) 0.78
Inpatient morbidity among HIV-infected male soldiers prior to their diagnosis of HIV infection. Am J Public Health (1991) 0.78
Lack of effect of concomitant zidovudine on rifabutin kinetics in patients with AIDS-related complex. Antimicrob Agents Chemother (1996) 0.77
Neurologic and psychiatric manifestations of HIV disease. J Gen Intern Med (1991) 0.77
Combination exposure to zidovudine plus sulfamethoxazole-trimethoprim diminishes B-lymphocyte immune responses to Pneumocystis murina infection in healthy mice. Clin Vaccine Immunol (2006) 0.77
Zidovudine (Retrovir) update. CMAJ (1990) 0.77
Preventing secondary infections among HIV-positive persons. Public Health Rep (1991) 0.76
The effects of twice and four times daily zidovudine on p24 antigenaemia in CDC stage II/III patients. Genitourin Med (1991) 0.76
Tumor necrosis factor and interferon as prognostic markers in human immunodeficiency virus (HIV) infection. Infection (1991) 0.76
Zidovudine therapy in HIV infection: which patients should be treated and when. Br J Clin Pharmacol (1995) 0.76
Will we ever know when to treat HIV infection? BMJ (1996) 0.75
Early Clinical Signs and Symptoms of HIV Infection: Delaying progression to AIDS. Can Fam Physician (1992) 0.75
A Brief Chronicle of CD4 as a Biomarker for HIV/AIDS: A Tribute to the Memory of John L. Fahey. For Immunopathol Dis Therap (2016) 0.75
Ups and downs--and ups in the antiviral therapy of HIV infection. Genitourin Med (1996) 0.75
Resistance, remission, and qualitative differences in HIV chemotherapy. Emerg Infect Dis (1997) 0.75
Immunomodulatory effect of zidovudine (ZDV) on cytotoxic T lymphocytes previously exposed to ZDV. Antimicrob Agents Chemother (2002) 0.75
Evidence of alkaline phosphatase interference in a zidovudine radioimmunoassay. Antimicrob Agents Chemother (1994) 0.75
Caring for patients with HIV infection. Management plan for family physicians. Can Fam Physician (1993) 0.75
Clinical trials of antiretroviral drugs: the role of the MRC AIDS Therapeutic Trials Committee (ATTC) and the MRC Clinical Trials Unit (CTU). Br J Clin Pharmacol (2003) 0.75
Combinative interactions of a human immunodeficiency virus (HIV) Tat antagonist with HIV reverse transcriptase inhibitors and an HIV protease inhibitor. Antimicrob Agents Chemother (1994) 0.75
Molecular mechanisms of serotonergic action of the HIV-1 antiretroviral efavirenz. Pharmacol Res (2016) 0.75
Infectious diseases and AIDS. Postgrad Med J (1992) 0.75
Treatment of mildly symptomatic human immunodeficiency virus (HIV) infection. Ann Intern Med (1990) 0.75
Serum beta 2-microglobulin levels in asymptomatic HIV-1-infected subjects during long-term zidovudine treatment. Genitourin Med (1991) 0.75
Feedback from the Sixth International AIDS Conference, San Francisco 1990. Genitourin Med (1991) 0.75
Combination antiretroviral therapy. Back to the future. Drugs (1995) 0.75
Early versus delayed treatment of HIV infection. Zidovudine should be given before symptoms develop. Drugs (1995) 0.75
Correlation between antiretroviral resistance mutations, biological parameters, and clinical evolution in zidovudine-treated patients infected with human immunodeficiency virus type 1. Eur J Clin Microbiol Infect Dis (1997) 0.75
Recent advances in the medical management of early HIV disease. J Gen Intern Med (1991) 0.75
Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science (1997) 18.10
Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science (1997) 15.12
HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy. Science (1989) 14.63
The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. N Engl J Med (1987) 13.84
HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER Study. Neurology (2010) 12.32
Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med (1997) 10.62
Visualization by immune electron microscopy of a 27-nm particle associated with acute infectious nonbacterial gastroenteritis. J Virol (1972) 9.12
An outbreak of tuberculosis caused by multiple-drug-resistant tubercle bacilli among patients with HIV infection. Ann Intern Med (1992) 8.67
The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. N Engl J Med (1987) 8.52
Antiretroviral drug resistance testing in adult HIV-1 infection: recommendations of an International AIDS Society-USA Panel. JAMA (2000) 7.81
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy. Nature (2012) 7.76
Sexual transmission and propagation of SIV and HIV in resting and activated CD4+ T cells. Science (1999) 7.66
Ecology. Synthesizing U.S. river restoration efforts. Science (2005) 7.26
Isolation of HTLV-III from cerebrospinal fluid and neural tissues of patients with neurologic syndromes related to the acquired immunodeficiency syndrome. N Engl J Med (1985) 6.54
Antiretroviral therapy in adults: updated recommendations of the International AIDS Society-USA Panel. JAMA (2000) 6.49
Antiretroviral therapy for HIV infection in 1997. Updated recommendations of the International AIDS Society-USA panel. JAMA (1997) 6.35
Clinical and epidemiologic features of primary HIV infection. Ann Intern Med (1996) 6.04
Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. National Institute of Allergy and Infectious Diseases Mycoses Study Group and AIDS Clinical Trials Group. N Engl J Med (1997) 5.88
Isothermal, in vitro amplification of nucleic acids by a multienzyme reaction modeled after retroviral replication. Proc Natl Acad Sci U S A (1990) 5.85
Comparison of amphotericin B with fluconazole in the treatment of acute AIDS-associated cryptococcal meningitis. The NIAID Mycoses Study Group and the AIDS Clinical Trials Group. N Engl J Med (1992) 5.84
HIV-specific CD8(+) T cells produce antiviral cytokines but are impaired in cytolytic function. J Exp Med (2000) 5.79
Plasma viremia in human immunodeficiency virus infection. N Engl J Med (1989) 5.73
Practice guidelines for the management of cryptococcal disease. Infectious Diseases Society of America. Clin Infect Dis (2000) 5.53
Safety of and immunological response to a recombinant vaccinia virus vaccine expressing HIV envelope glycoprotein. Lancet (1991) 5.42
Extensive polymorphisms observed in HIV-1 clade B protease gene using high-density oligonucleotide arrays. Nat Med (1996) 5.35
Antiretroviral therapy for HIV infection in 1996. Recommendations of an international panel. International AIDS Society-USA. JAMA (1996) 5.29
Adenine arabinoside therapy of biopsy-proved herpes simplex encephalitis. National Institute of Allergy and Infectious Diseases collaborative antiviral study. N Engl J Med (1977) 5.02
A new acute transforming feline retrovirus and relationship of its oncogene v-kit with the protein kinase gene family. Nature (1986) 4.90
Evolution of organic aerosols in the atmosphere. Science (2009) 4.82
HIV viral load markers in clinical practice. Nat Med (1996) 4.78
A controlled trial comparing continued zidovudine with didanosine in human immunodeficiency virus infection. The NIAID AIDS Clinical Trials Group. N Engl J Med (1992) 4.71
Antiretroviral therapy for HIV infection in 1998: updated recommendations of the International AIDS Society-USA Panel. JAMA (1998) 4.61
Susceptibilities of zidovudine-susceptible and -resistant human immunodeficiency virus isolates to antiviral agents determined by using a quantitative plaque reduction assay. Antimicrob Agents Chemother (1990) 4.51
Antiretroviral drug resistance testing in adults with HIV infection: implications for clinical management. International AIDS Society--USA Panel. JAMA (1998) 4.42
The importance of nef in the induction of human immunodeficiency virus type 1 replication from primary quiescent CD4 lymphocytes. J Exp Med (1994) 4.39
Highly active antiretroviral therapy decreases mortality and morbidity in patients with advanced HIV disease. Ann Intern Med (2001) 4.26
Optimal infectivity in vitro of human immunodeficiency virus type 1 requires an intact nef gene. J Virol (1994) 4.14
Immunostimulatory DNA sequences function as T helper-1-promoting adjuvants. Nat Med (1997) 4.12
A controlled trial of amantadine and rimantadine in the prophylaxis of influenza A infection. N Engl J Med (1982) 4.04
Predictors of self-reported adherence and plasma HIV concentrations in patients on multidrug antiretroviral regimens. J Acquir Immune Defic Syndr (2000) 4.03
Transmission of acute infectious nonbacterial gastroenteritis to volunteers by oral administration of stool filtrates. J Infect Dis (1971) 3.88
Diagnosis of primary HIV-1 infection. Los Angeles County Primary HIV Infection Recruitment Network. Ann Intern Med (2001) 3.80
Prevalence and predictive value of intermittent viremia with combination hiv therapy. JAMA (2001) 3.73
Invasion of the central nervous system by Treponema pallidum: implications for diagnosis and treatment. Ann Intern Med (1988) 3.71
Interferons and bacterial lipopolysaccharide protect macrophages from productive infection by human immunodeficiency virus in vitro. J Exp Med (1989) 3.63
Incidence and natural history of cytomegalovirus disease in patients with advanced human immunodeficiency virus disease treated with zidovudine. The Zidovudine Epidemiology Study Group. J Infect Dis (1992) 3.61
Clinical presentation and outcome of patients with HIV infection and tuberculosis caused by multiple-drug-resistant bacilli. Ann Intern Med (1992) 3.59
Viral dynamics of acute HIV-1 infection. J Exp Med (1999) 3.45
Accelerated bone mineral loss in HIV-infected patients receiving potent antiretroviral therapy. AIDS (2000) 3.39
Amphotericin B: current understanding of mechanisms of action. Antimicrob Agents Chemother (1990) 3.26
Cytomegalovirus infection induces high levels of cyclins, phosphorylated Rb, and p53, leading to cell cycle arrest. J Virol (1995) 3.18
Proposal for naming host cell-derived inserts in retrovirus genomes. J Virol (1981) 3.18
Immunoglobulin G(Fc)-binding receptors on virions of herpes simplex virus type 1 and transfer of these receptors to the cell surface by infection. J Virol (1980) 3.16
Comparison of three agents of acute infectious nonbacterial gastroenteritis by cross-challenge in volunteers. J Infect Dis (1974) 3.10
Association between culturable human immunodeficiency virus type 1 (HIV-1) in semen and HIV-1 RNA levels in semen and blood: evidence for compartmentalization of HIV-1 between semen and blood. J Infect Dis (1998) 2.98
Heterogeneous clearance rates of long-lived lymphocytes infected with HIV: intrinsic stability predicts lifelong persistence. Proc Natl Acad Sci U S A (2003) 2.95
Biological properties of Norwalk agent of acute infectious nonbacterial gastroenteritis. Proc Soc Exp Biol Med (1972) 2.94
Drug susceptibility in HIV infection after viral rebound in patients receiving indinavir-containing regimens. JAMA (2000) 2.91
A preliminary study of ritonavir, an inhibitor of HIV-1 protease, to treat HIV-1 infection. N Engl J Med (1995) 2.88
Subtypes of Legionella pneumophila serogroup 1 associated with different attack rates. Lancet (1983) 2.87
Location of the structural genes for glycoproteins gD and gE and for other polypeptides in the S component of herpes simplex virus type 1 DNA. J Virol (1982) 2.85
Establishment of a stable, inducible form of human immunodeficiency virus type 1 DNA in quiescent CD4 lymphocytes in vitro. J Virol (1995) 2.85
Reduced antiretroviral drug susceptibility among patients with primary HIV infection. JAMA (1999) 2.82
Apoptosis as a mechanism of cell death in cultured T lymphoblasts acutely infected with HIV-1. J Clin Invest (1991) 2.82
In vivo compartmentalization of human immunodeficiency virus: evidence from the examination of pol sequences from autopsy tissues. J Virol (1997) 2.71
Preferential replication of HIV-1 in the CD45RO memory cell subset of primary CD4 lymphocytes in vitro. J Clin Invest (1997) 2.69
Glycoprotein gE of herpes simplex virus type 1: effects of anti-gE on virion infectivity and on virus-induced fc-binding receptors. J Virol (1982) 2.68
A comparison of immediate with deferred zidovudine therapy for asymptomatic HIV-infected adults with CD4 cell counts of 500 or more per cubic millimeter. AIDS Clinical Trials Group. N Engl J Med (1995) 2.66
Herpes simplex encephalitis: vidarabine therapy and diagnostic problems. N Engl J Med (1981) 2.56
Similarities and differences in the Fc-binding glycoprotein (gE) of herpes simplex virus types 1 and 2 and tentative mapping of the viral gene for this glycoprotein. J Virol (1982) 2.55
NIH conference. Herpes zoster-varicella infections in immunosuppressed patients. Ann Intern Med (1978) 2.52
A new reporter cell line to monitor HIV infection and drug susceptibility in vitro. Proc Natl Acad Sci U S A (1997) 2.52
Genomic evidence for a complete sexual cycle in Candida albicans. Proc Natl Acad Sci U S A (2001) 2.52
Nevirapine-resistant human immunodeficiency virus: kinetics of replication and estimated prevalence in untreated patients. J Virol (1996) 2.50
A randomized controlled trial of a reduced daily dose of zidovudine in patients with the acquired immunodeficiency syndrome. The AIDS Clinical Trials Group. N Engl J Med (1990) 2.50
Comparative performance of high-density oligonucleotide sequencing and dideoxynucleotide sequencing of HIV type 1 pol from clinical samples. AIDS Res Hum Retroviruses (1998) 2.50
A pilot study of low-dose zidovudine in human immunodeficiency virus infection. N Engl J Med (1990) 2.48
Evidence for early central nervous system involvement in the acquired immunodeficiency syndrome (AIDS) and other human immunodeficiency virus (HIV) infections. Studies with neuropsychologic testing and magnetic resonance imaging. Ann Intern Med (1987) 2.46
Nucleic acid amplification in vitro: detection of sequences with low copy numbers and application to diagnosis of human immunodeficiency virus type 1 infection. Clin Microbiol Rev (1989) 2.43
An objective case definition of lipodystrophy in HIV-infected adults: a case-control study. Lancet (2003) 2.43
Evolution of envelope sequences of human immunodeficiency virus type 1 in cellular reservoirs in the setting of potent antiviral therapy. J Virol (1999) 2.42
Potent neutralizing activity associated with anti-glycoprotein D specificity among monoclonal antibodies selected for binding to herpes simplex virions. J Virol (1985) 2.42
Metabolism and anti-human immunodeficiency virus-1 activity of 2-halo-2',3'-dideoxyadenosine derivatives. J Biol Chem (1988) 2.41
Producer-cell modification of human immunodeficiency virus type 1: Nef is a virion protein. J Virol (1996) 2.40
Prevalence of psychiatric disorders among men infected with human immunodeficiency virus. A controlled study. Arch Gen Psychiatry (1988) 2.36
Four viral genes independently contribute to attenuation of live influenza A/Ann Arbor/6/60 (H2N2) cold-adapted reassortant virus vaccines. J Virol (1988) 2.35
New enzyme immunoassays for measurement of influenza A/Victoria/3/75 virus in nasal washes. Lancet (1980) 2.35
Horizontal transmission of feline leukaemia virus. Nature (1973) 2.34
Neurologic relapse after benzathine penicillin therapy for secondary syphilis in a patient with HIV infection. N Engl J Med (1987) 2.32
Pulmonary cryptococcosis in patients without HIV infection. Chest (1999) 2.31
Nomenclature for antiviral-resistant human hepatitis B virus mutations in the polymerase region. Hepatology (2001) 2.30
A health status questionnaire using 30 items from the Medical Outcomes Study. Preliminary validation in persons with early HIV infection. Med Care (1991) 2.30
A waterborne outbreak of gastroenteritis with secondary person-to-person spread. Association with a viral agent. Lancet (1979) 2.29